Longboard Pharmaceuticals Net Income

Longboard Pharmaceuticals (LBPH) currently reports a net income of $-76M as of September 2024. That compares with $-50M in the prior-year period — down 53.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Longboard Pharmaceuticals's net income history and peer comparisons.

Longboard Pharmaceuticals's net income decreased from $-50M to $-76M — a 53.2% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Longboard Pharmaceuticals's net income of $-76M is lower than the Healthcare sector average of $16B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Longboard Pharmaceuticals reported $-76M in net income as of September 2024. That compares with $-50M in the prior-year period — down 53.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-76M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Longboard Pharmaceuticals, and consider following LBPH for alerts when major investors trade the stock.